Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02977065
Other study ID # 148HL16011
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date March 23, 2017
Est. completion date January 30, 2018

Study information

Verified date November 2018
Source Chong Kun Dang Pharmaceutical
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A multicenter, double-blind, parallel-group, active-controlled, dose-ranging study to assess the safety and efficacy of the novel cholesteryl ester transfer protein (CETP) inhibitor CKD-519 in combination with atorvastatin or rosuvastatin in subjects with dyslipidemia.


Description:

The purpose of this study is to assess the safety, efficacy, and tolerability of CKD-519, administered with HMG-CoA reductase inhibitors in subjects with dyslipidemia


Recruitment information / eligibility

Status Completed
Enrollment 62
Est. completion date January 30, 2018
Est. primary completion date December 30, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. Age 18 to 80 years.

2. Dyslipidemia with LDL-C

- At screening if untreated: 100 to 190 mg/dL

- At screening if treated with statins or other lipid-lowering drugs: 100 to 170 mg/dL

- At start of double-blind treatment: 100 to 190 mg/dL.

3. HDL-C <45 mg/dL (males) or <50 mg/dL (females).

4. Fasting TG <400 mg/dL.

5. Presence of the following conditions is permitted but not mandatory, at the discretion of the investigator:

- Treated and stable coronary heart disease without acute events in the past 3 months and stable, state-of-the-art medication.

- Treated and stable carotid artery disease or peripheral arterial disease on stable, standard medication for the past 3 months

- Treated and stable Type 2 diabetes mellitus with glycosylated hemoglobin (HbA1c) =9.5%.

6. Willing and able to sign the informed consent form (ICF).

Exclusion Criteria:

1. Chronic heart failure as defined by New York Heart Association classes III and IV.

2. Uncontrolled cardiac arrhythmias.

3. Myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft, or unstable angina in past 3 months before Visit 1.

4. Stroke or transient ischemic attack within 3 months before Visit 1.

5. Uncontrolled hypertension.

6. Clinically significant laboratory abnormalities

- Aspartate aminotransferase or alanine aminotransferase >2 times upper limit of normal range

- Bilirubin >1.5 times upper limit of normal range

- Creatine kinase >2 times upper limit of normal range.

7. Any active nephropathy or estimated glomerular filtration rate <60 mL/min/1.73m2 or on kidney dialysis.

8. Poorly controlled (thyroid-stimulating hormone [TSH] >2 times upper limit of normal) hyperthyroidism.

9. Homozygous familial hypercholesterolemia.

10. Intolerance or hypersensitivity to atorvastatin or rosuvastatin.

11. Prior treatment with any CETP inhibitor.

12. Positive for human immunodeficiency virus (HIV) positive, hepatitis B or hepatitis C.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Atorvastatin 20mg
PO daily for 4weeks
Atorvastatin 20 mg + CKD-519 50 mg
PO daily for 4weeks
Atorvastatin 20 mg + CKD-519 100 mg
PO daily for 4weeks
Atorvastatin 20 mg + CKD-519 200 mg
PO daily for 4weeks
Rosuvastatin 10 mg
PO daily for 4weeks
Rosuvastatin 10 mg + CKD-519 100 mg
PO daily for 4weeks

Locations

Country Name City State
Australia Not provided Adelaide

Sponsors (1)

Lead Sponsor Collaborator
Chong Kun Dang Pharmaceutical

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage change from baseline (Visit 3) in LDL-C at Week 4
Secondary Percentage change from baseline in HDL-C at Weeks 2 and Week 4
Secondary Percentage change from baseline in concentration of HDL particles (HDL-P) at Weeks 2 and 4
Secondary Change from baseline in size of HDL particles (HDL-P) at Weeks 2 and 4
Secondary Percentage change from baseline in LDL-C at Week 2
Secondary Change in concentration from baseline in LDL-C at Weeks 2 and 4
Secondary Change in concentration from baseline in HDL-C at Weeks 2 and 4
Secondary Percentage change from baseline in total cholesterol, TG, and non-HDL-C at Weeks 2 and 4
Secondary Change in concentration from baseline in total cholesterol, TG, and non-HDL-C at Weeks 2 and 4
Secondary Percentage change from baseline in apolipoprotein B (Apo B), apolipoprotein A1 (Apo A1), and apolipoprotein E (Apo E) at Weeks 2 and 4
Secondary Change in concentration from baseline in Apo B, Apo A1, and Apo E at Weeks 2 and 4
Secondary Percentage change from baseline in lipoprotein(a) (Lp-a) at Weeks 2 and 4
Secondary Change in concentration from baseline in Lp-a at Weeks 2 and 4
Secondary Change in concentration from baseline in high-sensitivity C-reactive protein at at Weeks 2 and 4
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Completed NCT04894318 - The Effect Of Low-Fat And Low-Cholesterol Dietary Intervention On LDL Sub-Groups In Turkısh Dyslipidemic Patients N/A
Completed NCT04862962 - Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin/Ezetimibe for Patients With Dyslipidaemia
Completed NCT04052594 - A Study of LY3475766 in Healthy Participants Phase 1
Active, not recruiting NCT04270084 - Metabolic Optimization Through Diet/Lifestyle Improvements For Youth N/A
Completed NCT03241121 - Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome N/A
Completed NCT04516291 - A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70) Phase 2
Completed NCT03170752 - Implementing and Testing a Cardiovascular Assessment Screening Program (CASP) N/A
Completed NCT05124847 - TREating Pediatric Obesity N/A
Completed NCT04186780 - Effects of Lentinula Edodes Bars on Dyslipidemia and Oxidative Stress in Cholesterol Individuals: Randomized Study N/A
Not yet recruiting NCT03674333 - Effect of Adding Folic Acid on Lipid Parameters in Population With Dyslipidemias N/A
Not yet recruiting NCT06159543 - The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes N/A
Terminated NCT01697735 - The Therapeutic Effects of Statins and Berberine on the Hyperlipemia Phase 4
Completed NCT00362908 - Effects of Low and Moderate Fat Diets on Lipids, Inflammation and Vascular Reactivity in the Metabolic Syndrome N/A
Completed NCT00455325 - Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS) Phase 2
Completed NCT00644709 - A Study Of Atorvastatin For The Treatment Of High Cholesterol In Patients At High Risk Of Coronary Heart Disease (CHD) Phase 4
Recruiting NCT05624658 - Effect of Combined Lipid-lowering Therapy on Atherosclerotic Plaque Vulnerability in Patients With ACS N/A
Recruiting NCT03988101 - Role of Statin in Venous Dysfunction in Patients With Venous Thromboembolism Event Phase 4
Recruiting NCT06024291 - Reducing Circulating Sphingolipid Levels to Optimise Cardiometabolic Health - The SphingoFIT Trial N/A
Completed NCT01218204 - A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin Phase 2